Post-earnings recap
Reported
Thu, Jul 30, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx reported a strong earnings per share, significantly exceeding expectations, which contributed to a positive stock reaction. The 1.77% increase in stock price reflects investor confidence in the company's performance, despite the lack of revenue details and guidance. The management's focus on patient support and pipeline advancement suggests a strategic approach moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | +126.25% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the earnings surprise, highlighting their commitment to ongoing projects. They emphasized patient support as a priority.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and supporting patients.